Oncomine is an amplicon-based targeted Next-Generation Sequencing (NGS) test for the identification of clinically significant somatic mutations from the DNA and RNA of 143 cancer-related genes. Alterations identified include single nucleotide variants (SNVs), insertions and deletions (indels), copy number alterations (CNAs), and oncogenic fusions (greater than 2,500 amplicons) in solid tumors.
Acceptable Specimens:
Formalin-fixed paraffin embedded tissue: One Hematoxylin and Eosin (H&E) slide and 15-20 unstained sections with a minimum of 20-percent neoplastic cellularity
Formalin-fixed cytology cell block: One H&E slide and 15-20 unstained cell block sections with a minimum of 20-percent neoplastic cellularity
Fine needle aspiration specimen: Cells suspended in CytoLyt or PreservCyt solution, preserved at room temperature no longer than eight days